Last reviewed · How we verify

NCT06863441

The Value of PET Imaging Targeting Granzyme B in Predicting Efficacy and Prognosis in T-NK Cell Lymphoma

Not yet recruiting Last updated 7 March 2025
What this trial tests

trial in T-NK Cell Lymphoma in 50 participants. Not yet recruiting.

Timeline
1 March 2025
Primary endpoint
31 December 2029
31 December 2029

Quick facts

Lead sponsorRuijin Hospital
StatusNot yet recruiting
Study typeOBSERVATIONAL
Enrollment50
Start date1 March 2025
Primary completion31 December 2029
Estimated completion31 December 2029
Sites1 location across China

Conditions studied

Sponsor

Ruijin Hospital

Who can join

18 and older, any sex, with T-NK Cell Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study on the value of PET imaging targeting granzyme B in predicting the efficacy and prognosis of T-NK cell lymphoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The application and prospect of granzyme B-targeted PET imaging in cancer immunotherapy.
    Tong X, Jiang Y, Bi N. · · 2025 · PMID 41361310 · DOI 10.1186/s12967-025-07419-w

Verify or expand the search:

Other Ruijin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06863441.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing